Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells

Medical Systems Biology Laboratory, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute, Houston, Texas 77030, USA.
Cancer Research (Impact Factor: 9.33). 10/2010; 70(19):7723-33. DOI: 10.1158/0008-5472.CAN-09-4360
Source: PubMed


Cancer cells with active drug efflux capability are multidrug resistant and pose a significant obstacle for the efficacy of chemotherapy. Moreover, recent evidence suggests that high drug efflux cancer cells (HDECC) may be selectively enriched with stem-like cancer cells, which are believed to be the cause for tumor initiation and recurrence. There is a great need for therapeutic reagents that are capable of eliminating HDECCs. We developed an image-based high-content screening (HCS) system to specifically identify and analyze the HDECC population in lung cancer cells. Using the system, we screened 1,280 pharmacologically active compounds that identified 12 potent HDECC inhibitors. It is shown that these inhibitors are able to overcome multidrug resistance (MDR) and sensitize HDECCs to chemotherapeutic drugs, or directly reduce the tumorigenicity of lung cancer cells possibly by affecting stem-like cancer cells. The HCS system we established provides a new approach for identifying therapeutic reagents overcoming MDR. The compounds identified by the screening may potentially be used as potential adjuvant to improve the efficacy of chemotherapeutic drugs.

Download full-text


Available from: Stephen TC Wong, Feb 26, 2014
31 Reads
  • Source
    • "PTP4A3 has been reported to mediate both p53 and TGFβ signaling which are well described mediators of cell fate and tumorigenesis (Jiang et al., 2011; Basak et al., 2008). Additionally, a recent report observed that a PTP4A3 small molecule inhibitor prevents the tumorigenesis of human lung cancer stem cells and sensitizes them to combination chemotherapy (Xia et al., 2010). Therefore, it is possible that PTP4A3 has an important role in the tumorigenicity of tumor-initiating cells of colon cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The PTP4A3 gene is highly expressed in human colon cancer and often associates with enhanced metastatic potential. Genetic disruption of the mouse Ptp4a3 gene reduces the frequency of colon tumor formation in mice treated in a colitis-associated cancer model. In the current study, we have examined the role of Ptp4a3 in the tumor-initiating cell population of mouse colon tumors using an in vitro culture system. Tumors generated in vivo following AOM/DSS treatment were isolated, dissociated, and expanded on a feeder layer resulting in a CD133+ cell population, which expressed high levels of Ptp4a3. Tumor cells deficient for Ptp4a3 exhibited reduced clonogenicity and growth potential relative to WT cells as determined by limiting dilution analysis. Importantly, expanded tumor cells from WT mice readily formed secondary tumors when transplanted into nude mice, while tumor cells without Ptp4a3 expression failed to form secondary tumors and thus were not tumorigenic. These results demonstrate that Ptp4a3 contributes to the malignant phenotype of tumor-initiating cells and supports its role as a potential therapeutic target to inhibit tumor self-renewal and metastasis.
    Stem Cell Research 07/2014; 13(1). DOI:10.1016/j.scr.2014.05.004 · 3.69 Impact Factor
  • Strahlentherapie und Onkologie 11/2012; 188(3). DOI:10.1007/s00066-012-0207-z · 2.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The AACR-NCI Conference "Systems Biology: Confronting the Complexity of Cancer" took place from February 27 to March 2, 2011, in San Diego, CA. Several themes resonated during the meeting, notably (i) the need for better methods to distill insights from large-scale networks, (ii) the importance of integrating multiple data types in constructing more realistic models, (iii) challenges in translating insights about tumorigenic mechanisms into therapeutic interventions, and (iv) the role of the tumor microenvironment, at the physical, cellular, and molecular levels. The meeting highlighted concrete applications of systems biology to cancer, and the value of collaboration between interdisciplinary researchers in attacking formidable problems.
    Cancer Research 09/2011; 71(18):5961-4. DOI:10.1158/0008-5472.CAN-11-1569 · 9.33 Impact Factor
Show more